top of page

on the pen doesn't exist without your


I'm Dave. On The Pen is my thing. My passion. But so are my 4 kids, and so is my day job. In order to sustain my efforts, I have to cover the costs involved with OTP. The website, the programs that make it pretty, and the tools that help people connect to it. A gift of ANY amount is greatly appreciated!

Untitled design (4).png

Tirzepatide Shows Promise in Treating MASH: Key Findings from the SYNERGY-NASH Study

Significant Results in MASH Treatment

Eli Lilly recently announced the results of their phase 2 SYNERGY-NASH study, which investigated the use of tirzepatide in treating metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis. This condition, previously known as nonalcoholic steatohepatitis (NASH), is a serious liver disease that often progresses to cirrhosis and liver failure.

Key Outcomes

1. MASH Resolution Without Worsening of Fibrosis

- Placebo: Only 13.2% of participants showed MASH resolution without fibrosis worsening.

- 5 mg Tirzepatide: 51.8% achieved this outcome.

- 10 mg Tirzepatide: 62.8% achieved this outcome.

- 15 mg Tirzepatide: 73.3% achieved this outcome.

These results demonstrate a clear dose-response relationship, with higher doses of tirzepatide leading to better outcomes.

2. Fibrosis Improvement Without Worsening of MASH

- Placebo: 32.8% saw a 1-stage or greater improvement in fibrosis.

- 5 mg Tirzepatide: 59.1% saw improvement.

- 10 mg Tirzepatide: 53.3% saw improvement.

- 15 mg Tirzepatide: 54.2% saw improvement.

3. Additional Benefits

- Participants taking tirzepatide also experienced significant improvements in body weight, blood markers of liver injury, and biomarkers of liver fat, inflammation, and fibrosis.

Expert Commentary

Dr. Rohit Loomba from the University of California San Diego School of Medicine emphasized the importance of these findings, noting the urgent need for treatments capable of slowing MASH progression and reducing severe health complications.

Safety Profile

The safety profile of tirzepatide in this study was consistent with previous trials (SURMOUNT and SURPASS), with the most common side effects being gastrointestinal-related and generally mild to moderate in severity.

Future Steps

Eli Lilly is in discussions with regulatory authorities to determine the next steps for tirzepatide as a treatment for MASH. Given the significant impact MASH has on millions of adults, the potential of tirzepatide to offer a clinically meaningful treatment effect is promising.

About the Study and Tirzepatide

SYNERGY-NASH Study: A multicenter, double-blind, randomized, placebo-controlled phase 2 trial with 190 participants. It evaluated the efficacy and safety of tirzepatide in adults with biopsy-confirmed MASH and stage 2 or 3 fibrosis over 52 weeks.

Tirzepatide: A once-weekly dual GIP and GLP-1 receptor agonist, approved as Mounjaro for type 2 diabetes treatment and under investigation for other conditions, including obesity, sleep apnea, and chronic kidney disease.

For further details, the full study results were presented at the European Association for the Study of the Liver (EASL) Congress 2024 and published in The New England Journal of Medicine.

Stay informed, stay safe, and always stay in touch with the latest news by getting alerts at

271 views2 comments


Yes, I agree. Stop calling it. A weight loss drug. It’s more than that. DAVE I’d like to donate but I don’t use those apps can you let me know another way to contribute? Thank you. I just love your post and I hope your son and wife are doing better.

Dave Knapp
Dave Knapp
Jun 12
Replying to

Hi Tina! That’s so kind of you to want to contribute to the cause! Send me an email to if you’d like :)

bottom of page